Clinical trials of new drugs for Alzheimer disease
Alzheimer disease (AD) accounts for 60–70% of dementia cases. Given the seriousness of the disease and continual increase in patient numbers, developing effective therapies to treat AD has become urgent. Presently, the drugs available for AD treatment, including cholinesterase inhibitors and an anta...
Saved in:
| Published in | Journal of biomedical science Vol. 27; no. 1; pp. 18 - 13 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
06.01.2020
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Alzheimer disease (AD) accounts for 60–70% of dementia cases. Given the seriousness of the disease and continual increase in patient numbers, developing effective therapies to treat AD has become urgent. Presently, the drugs available for AD treatment, including cholinesterase inhibitors and an antagonist of the N-methyl-D-aspartate receptor, can only inhibit dementia symptoms for a limited period of time but cannot stop or reverse disease progression. On the basis of the amyloid hypothesis, many global drug companies have conducted many clinical trials on amyloid clearing therapy but without success. Thus, the amyloid hypothesis may not be completely feasible. The number of anti-amyloid trials decreased in 2019, which might be a turning point. An in-depth and comprehensive understanding of the contribution of amyloid beta and other factors of AD is crucial for developing novel pharmacotherapies.
In ongoing clinical trials, researchers have developed and are testing several possible interventions aimed at various targets, including anti-amyloid and anti-tau interventions, neurotransmitter modification, anti-neuroinflammation and neuroprotection interventions, and cognitive enhancement, and interventions to relieve behavioral psychological symptoms. In this article, we present the current state of clinical trials for AD at
clinicaltrials.gov
. We reviewed the underlying mechanisms of these trials, tried to understand the reason why prior clinical trials failed, and analyzed the future trend of AD clinical trials. |
|---|---|
| AbstractList | Alzheimer disease (AD) accounts for 60-70% of dementia cases. Given the seriousness of the disease and continual increase in patient numbers, developing effective therapies to treat AD has become urgent. Presently, the drugs available for AD treatment, including cholinesterase inhibitors and an antagonist of the N-methyl-D-aspartate receptor, can only inhibit dementia symptoms for a limited period of time but cannot stop or reverse disease progression. On the basis of the amyloid hypothesis, many global drug companies have conducted many clinical trials on amyloid clearing therapy but without success. Thus, the amyloid hypothesis may not be completely feasible. The number of anti-amyloid trials decreased in 2019, which might be a turning point. An in-depth and comprehensive understanding of the contribution of amyloid beta and other factors of AD is crucial for developing novel pharmacotherapies.In ongoing clinical trials, researchers have developed and are testing several possible interventions aimed at various targets, including anti-amyloid and anti-tau interventions, neurotransmitter modification, anti-neuroinflammation and neuroprotection interventions, and cognitive enhancement, and interventions to relieve behavioral psychological symptoms. In this article, we present the current state of clinical trials for AD at clinicaltrials.gov. We reviewed the underlying mechanisms of these trials, tried to understand the reason why prior clinical trials failed, and analyzed the future trend of AD clinical trials.Alzheimer disease (AD) accounts for 60-70% of dementia cases. Given the seriousness of the disease and continual increase in patient numbers, developing effective therapies to treat AD has become urgent. Presently, the drugs available for AD treatment, including cholinesterase inhibitors and an antagonist of the N-methyl-D-aspartate receptor, can only inhibit dementia symptoms for a limited period of time but cannot stop or reverse disease progression. On the basis of the amyloid hypothesis, many global drug companies have conducted many clinical trials on amyloid clearing therapy but without success. Thus, the amyloid hypothesis may not be completely feasible. The number of anti-amyloid trials decreased in 2019, which might be a turning point. An in-depth and comprehensive understanding of the contribution of amyloid beta and other factors of AD is crucial for developing novel pharmacotherapies.In ongoing clinical trials, researchers have developed and are testing several possible interventions aimed at various targets, including anti-amyloid and anti-tau interventions, neurotransmitter modification, anti-neuroinflammation and neuroprotection interventions, and cognitive enhancement, and interventions to relieve behavioral psychological symptoms. In this article, we present the current state of clinical trials for AD at clinicaltrials.gov. We reviewed the underlying mechanisms of these trials, tried to understand the reason why prior clinical trials failed, and analyzed the future trend of AD clinical trials. Alzheimer disease (AD) accounts for 60–70% of dementia cases. Given the seriousness of the disease and continual increase in patient numbers, developing effective therapies to treat AD has become urgent. Presently, the drugs available for AD treatment, including cholinesterase inhibitors and an antagonist of the N-methyl-D-aspartate receptor, can only inhibit dementia symptoms for a limited period of time but cannot stop or reverse disease progression. On the basis of the amyloid hypothesis, many global drug companies have conducted many clinical trials on amyloid clearing therapy but without success. Thus, the amyloid hypothesis may not be completely feasible. The number of anti-amyloid trials decreased in 2019, which might be a turning point. An in-depth and comprehensive understanding of the contribution of amyloid beta and other factors of AD is crucial for developing novel pharmacotherapies. In ongoing clinical trials, researchers have developed and are testing several possible interventions aimed at various targets, including anti-amyloid and anti-tau interventions, neurotransmitter modification, anti-neuroinflammation and neuroprotection interventions, and cognitive enhancement, and interventions to relieve behavioral psychological symptoms. In this article, we present the current state of clinical trials for AD at clinicaltrials.gov. We reviewed the underlying mechanisms of these trials, tried to understand the reason why prior clinical trials failed, and analyzed the future trend of AD clinical trials. Alzheimer disease (AD) accounts for 60-70% of dementia cases. Given the seriousness of the disease and continual increase in patient numbers, developing effective therapies to treat AD has become urgent. Presently, the drugs available for AD treatment, including cholinesterase inhibitors and an antagonist of the N-methyl-D-aspartate receptor, can only inhibit dementia symptoms for a limited period of time but cannot stop or reverse disease progression. On the basis of the amyloid hypothesis, many global drug companies have conducted many clinical trials on amyloid clearing therapy but without success. Thus, the amyloid hypothesis may not be completely feasible. The number of anti-amyloid trials decreased in 2019, which might be a turning point. An in-depth and comprehensive understanding of the contribution of amyloid beta and other factors of AD is crucial for developing novel pharmacotherapies. In ongoing clinical trials, researchers have developed and are testing several possible interventions aimed at various targets, including anti-amyloid and anti-tau interventions, neurotransmitter modification, anti-neuroinflammation and neuroprotection interventions, and cognitive enhancement, and interventions to relieve behavioral psychological symptoms. In this article, we present the current state of clinical trials for AD at clinicaltrials.gov. We reviewed the underlying mechanisms of these trials, tried to understand the reason why prior clinical trials failed, and analyzed the future trend of AD clinical trials. Keywords: Alzheimer disease, Clinical trials of drugs, Neuroinflammation, Neuroprotection, Anti-amyloid, Anti-tau, Cognitive enhancement Alzheimer disease (AD) accounts for 60–70% of dementia cases. Given the seriousness of the disease and continual increase in patient numbers, developing effective therapies to treat AD has become urgent. Presently, the drugs available for AD treatment, including cholinesterase inhibitors and an antagonist of the N-methyl-D-aspartate receptor, can only inhibit dementia symptoms for a limited period of time but cannot stop or reverse disease progression. On the basis of the amyloid hypothesis, many global drug companies have conducted many clinical trials on amyloid clearing therapy but without success. Thus, the amyloid hypothesis may not be completely feasible. The number of anti-amyloid trials decreased in 2019, which might be a turning point. An in-depth and comprehensive understanding of the contribution of amyloid beta and other factors of AD is crucial for developing novel pharmacotherapies. In ongoing clinical trials, researchers have developed and are testing several possible interventions aimed at various targets, including anti-amyloid and anti-tau interventions, neurotransmitter modification, anti-neuroinflammation and neuroprotection interventions, and cognitive enhancement, and interventions to relieve behavioral psychological symptoms. In this article, we present the current state of clinical trials for AD at clinicaltrials.gov . We reviewed the underlying mechanisms of these trials, tried to understand the reason why prior clinical trials failed, and analyzed the future trend of AD clinical trials. Alzheimer disease (AD) accounts for 60-70% of dementia cases. Given the seriousness of the disease and continual increase in patient numbers, developing effective therapies to treat AD has become urgent. Presently, the drugs available for AD treatment, including cholinesterase inhibitors and an antagonist of the N-methyl-D-aspartate receptor, can only inhibit dementia symptoms for a limited period of time but cannot stop or reverse disease progression. On the basis of the amyloid hypothesis, many global drug companies have conducted many clinical trials on amyloid clearing therapy but without success. Thus, the amyloid hypothesis may not be completely feasible. The number of anti-amyloid trials decreased in 2019, which might be a turning point. An in-depth and comprehensive understanding of the contribution of amyloid beta and other factors of AD is crucial for developing novel pharmacotherapies. Abstract Alzheimer disease (AD) accounts for 60–70% of dementia cases. Given the seriousness of the disease and continual increase in patient numbers, developing effective therapies to treat AD has become urgent. Presently, the drugs available for AD treatment, including cholinesterase inhibitors and an antagonist of the N-methyl-D-aspartate receptor, can only inhibit dementia symptoms for a limited period of time but cannot stop or reverse disease progression. On the basis of the amyloid hypothesis, many global drug companies have conducted many clinical trials on amyloid clearing therapy but without success. Thus, the amyloid hypothesis may not be completely feasible. The number of anti-amyloid trials decreased in 2019, which might be a turning point. An in-depth and comprehensive understanding of the contribution of amyloid beta and other factors of AD is crucial for developing novel pharmacotherapies. In ongoing clinical trials, researchers have developed and are testing several possible interventions aimed at various targets, including anti-amyloid and anti-tau interventions, neurotransmitter modification, anti-neuroinflammation and neuroprotection interventions, and cognitive enhancement, and interventions to relieve behavioral psychological symptoms. In this article, we present the current state of clinical trials for AD at clinicaltrials.gov. We reviewed the underlying mechanisms of these trials, tried to understand the reason why prior clinical trials failed, and analyzed the future trend of AD clinical trials. |
| ArticleNumber | 18 |
| Audience | Academic |
| Author | Huang, Li-Kai Chao, Shu-Ping Hu, Chaur-Jong |
| Author_xml | – sequence: 1 givenname: Li-Kai surname: Huang fullname: Huang, Li-Kai – sequence: 2 givenname: Shu-Ping surname: Chao fullname: Chao, Shu-Ping – sequence: 3 givenname: Chaur-Jong surname: Hu fullname: Hu, Chaur-Jong |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/31906949$$D View this record in MEDLINE/PubMed |
| BookMark | eNp1kl9vFCEUxYmpse3qB_DFTOKLL1u5wMDwYrLZ-KdJE1_0mQADWzazQ4UZjX5673Zb7TaaCRly-Z1D7uWck5Mxj4GQl0AvADr5tgLTTC8p4JJUL9UTcgaCcawwdfJgf0rOa91SCq3u1DNyykFTqYU-I2w9pDF5OzRTSXaoTY7NGH40fZk3tYm5NKvh13VIu1CaPtVga3hOnkYkw4u7_4J8_fD-y_rT8urzx8v16mrpJZPTsmVU8QBBQe-c9ELHVtHowNtOtFhQkgcmolXURaV9ANsG4UR0FjqmRc8X5PLg22e7NTcl7Wz5abJN5raQy8bYMiU_BCMFdbJ1VvAOhGNcQwc966J2PQhLOXq9O3jdzG4Xeh_GqdjhyPT4ZEzXZpO_G5wS17cGb-4MSv42hzqZXao-DIMdQ56rYZzjsLVgEtHXj9BtnsuIo0JK4NwZ7_RfamOxgTTGjPf6valZSeiUYoDgglz8g8KvD7vkMQ0xYf1I8Opho386vH9xBNQB8CXXWkI0Pk12SnnfdxoMULPPljlky2C2zD5bRqESHinvzf-v-Q2VkM1b |
| CitedBy_id | crossref_primary_10_1007_s44192_023_00057_y crossref_primary_10_1002_iub_2613 crossref_primary_10_1007_s12035_023_03791_0 crossref_primary_10_1007_s40120_023_00473_w crossref_primary_10_1002_trc2_12292 crossref_primary_10_1002_trc2_12170 crossref_primary_10_1080_21507740_2021_1941406 crossref_primary_10_1016_j_neuroscience_2024_11_078 crossref_primary_10_2174_1568026623666221228140450 crossref_primary_10_1007_s11357_025_01550_8 crossref_primary_10_1007_s00702_021_02457_2 crossref_primary_10_1134_S2079057022020175 crossref_primary_10_1016_j_ceca_2021_102362 crossref_primary_10_1016_S1627_4830_20_30194_X crossref_primary_10_1097_CM9_0000000000002914 crossref_primary_10_1016_j_bmcl_2021_128275 crossref_primary_10_3233_JAD_200488 crossref_primary_10_3389_fnins_2020_625348 crossref_primary_10_1016_j_neulet_2020_135464 crossref_primary_10_1177_13872877251322978 crossref_primary_10_1055_a_2052_8462 crossref_primary_10_1016_j_arr_2021_101333 crossref_primary_10_1016_j_ejmech_2021_113819 crossref_primary_10_1016_j_tins_2021_11_006 crossref_primary_10_1016_j_biopha_2024_117235 crossref_primary_10_3390_ijms22073330 crossref_primary_10_3233_JAD_201106 crossref_primary_10_3390_molecules25245789 crossref_primary_10_1021_acschemneuro_2c00720 crossref_primary_10_1002_brb3_3599 crossref_primary_10_3389_fnagi_2021_721858 crossref_primary_10_3389_fnagi_2021_687530 crossref_primary_10_3389_fnagi_2023_1238065 crossref_primary_10_1016_j_ejphar_2024_176879 crossref_primary_10_1038_s41598_022_20963_5 crossref_primary_10_1097_WAD_0000000000000580 crossref_primary_10_3389_fncel_2024_1449063 crossref_primary_10_1371_journal_pone_0281003 crossref_primary_10_1038_s41598_021_94706_3 crossref_primary_10_1186_s41983_023_00775_8 crossref_primary_10_1016_j_jconrel_2022_01_044 crossref_primary_10_3389_fphar_2023_1196413 crossref_primary_10_1007_s40120_023_00460_1 crossref_primary_10_1080_14756366_2020_1835882 crossref_primary_10_1001_jamahealthforum_2020_1148 crossref_primary_10_1057_s41271_022_00356_8 crossref_primary_10_3390_biomedicines9091126 crossref_primary_10_1016_j_dscb_2023_100076 crossref_primary_10_1016_j_jmgm_2023_108471 crossref_primary_10_1186_s13195_021_00874_9 crossref_primary_10_3389_fgene_2023_1175864 crossref_primary_10_1002_cbdv_202400402 crossref_primary_10_2139_ssrn_4113642 crossref_primary_10_3233_JAD_210171 crossref_primary_10_3389_fcell_2021_683459 crossref_primary_10_54097_hset_v36i_5794 crossref_primary_10_1016_j_arr_2024_102389 crossref_primary_10_1080_14737175_2022_2149324 crossref_primary_10_3389_fphar_2023_1228148 crossref_primary_10_51847_YJQDk2wtgX crossref_primary_10_1016_j_freeradbiomed_2022_01_025 crossref_primary_10_3390_ijms241311152 crossref_primary_10_3390_ijms21186664 crossref_primary_10_3389_fnagi_2021_760920 crossref_primary_10_3389_fradi_2023_1305390 crossref_primary_10_1016_j_jddst_2023_105047 crossref_primary_10_1080_17460441_2021_1838483 crossref_primary_10_1155_2022_8902262 crossref_primary_10_1016_j_bbii_2024_100048 crossref_primary_10_3390_neuroglia4030014 crossref_primary_10_1016_j_compbiomed_2024_108116 crossref_primary_10_18632_aging_204706 crossref_primary_10_3389_fphar_2022_1011740 crossref_primary_10_1016_j_drudis_2024_104164 crossref_primary_10_2147_ITT_S455881 crossref_primary_10_3389_fnagi_2021_735611 crossref_primary_10_1002_alz_12546 crossref_primary_10_3233_JAD_210110 crossref_primary_10_1126_sciadv_adr8841 crossref_primary_10_15212_AMM_2023_0001 crossref_primary_10_1016_j_ejphar_2023_176230 crossref_primary_10_3389_fnagi_2021_721937 crossref_primary_10_26599_FSHW_2022_9250094 crossref_primary_10_1007_s40120_023_00492_7 crossref_primary_10_1016_j_abb_2021_109022 crossref_primary_10_1016_j_ymthe_2022_08_010 crossref_primary_10_3390_ijms241512527 crossref_primary_10_1080_16583655_2024_2403813 crossref_primary_10_1002_biof_1936 crossref_primary_10_1002_jcsm_12830 crossref_primary_10_1002_dad2_12216 crossref_primary_10_1021_acsptsci_9b00104 crossref_primary_10_1016_j_arr_2024_102193 crossref_primary_10_1186_s13020_021_00514_2 crossref_primary_10_3389_fnins_2023_1197094 crossref_primary_10_1515_revneuro_2022_0021 crossref_primary_10_3389_fnagi_2023_1207012 crossref_primary_10_3389_fphar_2022_877872 crossref_primary_10_3389_fnagi_2021_720715 crossref_primary_10_3390_cells10082164 crossref_primary_10_3390_ijms232213954 crossref_primary_10_3390_molecules27196189 crossref_primary_10_3103_S0891416823030084 crossref_primary_10_3390_molecules29194780 crossref_primary_10_3390_ma15030804 crossref_primary_10_1038_s41598_021_97334_z crossref_primary_10_1111_acel_13221 crossref_primary_10_1002_mds_29298 crossref_primary_10_1016_j_progpolymsci_2021_101489 crossref_primary_10_1038_s41467_021_22491_8 crossref_primary_10_1016_j_ejmech_2020_112766 crossref_primary_10_2174_1568026623666221026091010 crossref_primary_10_1186_s13195_022_01125_1 crossref_primary_10_1016_j_nbd_2023_106202 crossref_primary_10_3233_JAD_200870 crossref_primary_10_1021_acsptsci_4c00149 crossref_primary_10_1080_07391102_2023_2251052 crossref_primary_10_31083_FBL25551 crossref_primary_10_1513_AnnalsATS_202205_380ST crossref_primary_10_3389_fnagi_2024_1443309 crossref_primary_10_3390_antiox10091428 crossref_primary_10_3390_membranes11100796 crossref_primary_10_1159_000511506 crossref_primary_10_1096_fj_202201197R crossref_primary_10_18632_aging_203485 crossref_primary_10_1016_j_genrep_2022_101534 crossref_primary_10_3389_fneur_2021_628368 crossref_primary_10_3389_fphar_2021_690256 crossref_primary_10_3390_nu15153389 crossref_primary_10_1016_j_jep_2024_119148 crossref_primary_10_1177_11795735211029113 crossref_primary_10_1186_s40035_024_00423_y crossref_primary_10_1186_s13195_021_00831_6 crossref_primary_10_1016_j_addr_2022_114537 crossref_primary_10_2174_1567205017666200528162046 crossref_primary_10_1016_j_mam_2020_100867 crossref_primary_10_3390_microorganisms10091848 crossref_primary_10_1021_acschemneuro_1c00210 crossref_primary_10_1080_07391102_2021_2016488 crossref_primary_10_1002_mas_21775 crossref_primary_10_1016_j_jfutfo_2022_03_016 crossref_primary_10_1111_jnc_15027 crossref_primary_10_1016_j_heliyon_2022_e12366 crossref_primary_10_2478_raon_2021_0051 crossref_primary_10_3389_fnmol_2023_1225227 crossref_primary_10_1016_j_measurement_2023_113274 crossref_primary_10_1055_s_0041_1737343 crossref_primary_10_55262_fabadeczacilik_1128446 crossref_primary_10_1007_s00439_020_02230_7 crossref_primary_10_1186_s12964_021_00799_8 crossref_primary_10_3233_JAD_200413 crossref_primary_10_1016_j_neuron_2023_04_018 crossref_primary_10_3233_JAD_220261 crossref_primary_10_1172_JCI168215 crossref_primary_10_3390_biom13111613 crossref_primary_10_3390_molecules25246001 crossref_primary_10_1021_acschemneuro_2c00328 crossref_primary_10_1038_s42003_022_04011_6 crossref_primary_10_2174_1389557522666220420094317 crossref_primary_10_1097_RLU_0000000000004252 crossref_primary_10_1039_D1CC04053G crossref_primary_10_2174_0113894501320096240627071400 crossref_primary_10_51847_ViC6sAGCyq crossref_primary_10_1007_s00115_022_01275_5 crossref_primary_10_1371_journal_pone_0258879 crossref_primary_10_1016_j_arr_2024_102309 crossref_primary_10_1016_j_bbi_2023_04_015 crossref_primary_10_1016_j_pneurobio_2021_102031 crossref_primary_10_1021_acschemneuro_1c00235 crossref_primary_10_1016_j_bioorg_2022_106322 crossref_primary_10_1016_j_neuroimage_2021_118302 crossref_primary_10_3233_JAD_210454 crossref_primary_10_1021_acschemneuro_3c00393 crossref_primary_10_14283_jpad_2020_12 crossref_primary_10_1007_s00401_022_02483_8 crossref_primary_10_1021_acschemneuro_4c00360 crossref_primary_10_3390_bioengineering10091093 crossref_primary_10_1007_s11357_021_00357_7 crossref_primary_10_1186_s12974_020_01967_2 crossref_primary_10_1186_s12929_023_00976_6 crossref_primary_10_3390_molecules25071659 crossref_primary_10_1038_s41598_023_34355_w crossref_primary_10_1016_j_jep_2021_114598 crossref_primary_10_1136_jim_2020_001297 crossref_primary_10_3390_ijms21072658 crossref_primary_10_2478_cpp_2021_0006 crossref_primary_10_1007_s11010_023_04922_w crossref_primary_10_1111_febs_17099 crossref_primary_10_2174_2211556011666220510141329 crossref_primary_10_1177_10398562221121215 crossref_primary_10_3390_biom11101541 crossref_primary_10_1007_s13311_022_01236_5 crossref_primary_10_3390_pharmaceutics15092271 crossref_primary_10_3233_ADR_220016 crossref_primary_10_2174_2210315513666230123111541 crossref_primary_10_1186_s13195_022_01124_2 crossref_primary_10_1111_bph_16065 crossref_primary_10_1016_j_jmgm_2023_108558 crossref_primary_10_1080_14728222_2020_1805734 crossref_primary_10_1002_ptr_8200 crossref_primary_10_1016_j_drudis_2022_06_005 crossref_primary_10_1016_j_biopha_2022_113709 crossref_primary_10_1016_j_jchromb_2023_123766 crossref_primary_10_1134_S0006297923140055 crossref_primary_10_3233_JAD_210660 crossref_primary_10_3390_molecules29235744 crossref_primary_10_1016_j_drudis_2024_103914 crossref_primary_10_1186_s12974_023_02704_1 crossref_primary_10_3390_ijms232012265 crossref_primary_10_1111_cns_14914 crossref_primary_10_1016_j_bmc_2024_117628 crossref_primary_10_1016_j_ejmech_2020_113102 crossref_primary_10_1016_j_jcyt_2023_04_001 crossref_primary_10_3389_fnagi_2023_1285549 crossref_primary_10_1016_j_bcp_2020_114187 crossref_primary_10_1016_j_isci_2022_103869 crossref_primary_10_1002_cmdc_202000484 crossref_primary_10_1016_j_arr_2024_102229 crossref_primary_10_7717_peerj_cs_2538 crossref_primary_10_2174_1389450121999200819144544 crossref_primary_10_1002_ima_70029 crossref_primary_10_1016_j_arr_2024_102224 crossref_primary_10_2174_0115680266293212240405042540 crossref_primary_10_1016_j_gene_2021_145972 crossref_primary_10_1007_s11357_022_00591_7 crossref_primary_10_1016_j_ejmech_2021_113397 crossref_primary_10_3389_fnagi_2020_581767 crossref_primary_10_3390_ijms22031273 crossref_primary_10_3390_ijms241411241 crossref_primary_10_1016_j_ejphar_2022_175439 crossref_primary_10_1039_D3BM00400G crossref_primary_10_1002_alz_14477 crossref_primary_10_1021_acsbiomaterials_0c00743 crossref_primary_10_2174_1385272826666220914114544 crossref_primary_10_1016_j_bioorg_2021_105025 crossref_primary_10_1002_pep2_24289 crossref_primary_10_1186_s40035_021_00256_z crossref_primary_10_14283_jpad_2023_54 crossref_primary_10_1016_j_isci_2023_108744 crossref_primary_10_1016_j_phymed_2023_154695 crossref_primary_10_1038_s41598_024_60134_2 crossref_primary_10_1016_j_bios_2022_114619 crossref_primary_10_1016_j_drudis_2020_04_002 crossref_primary_10_3389_fchem_2022_874615 crossref_primary_10_1073_pnas_2304213120 crossref_primary_10_22159_ijcpr_2025v17i1_6039 crossref_primary_10_17116_molgen2023410313 crossref_primary_10_1109_TCBB_2022_3233869 crossref_primary_10_1177_02611929231157756 crossref_primary_10_1038_s41392_024_01911_3 crossref_primary_10_1186_s13195_023_01356_w crossref_primary_10_3390_jpm10030115 crossref_primary_10_4155_fmc_2023_0290 crossref_primary_10_1038_s41593_020_00778_1 crossref_primary_10_3390_ijms241310523 crossref_primary_10_1016_j_bbih_2024_100894 crossref_primary_10_1002_med_21699 crossref_primary_10_1016_j_biopha_2023_115450 crossref_primary_10_3390_jcm13020536 crossref_primary_10_3897_pharmacia_70_e113014 crossref_primary_10_33224_rrch_2022_67_10_12_01 crossref_primary_10_1007_s10787_023_01348_0 crossref_primary_10_1021_acsami_3c14709 crossref_primary_10_2174_1567205017666201008112002 crossref_primary_10_1177_13872877251321183 crossref_primary_10_1016_j_arabjc_2023_105300 crossref_primary_10_1136_jnnp_2020_324942 crossref_primary_10_3390_biom12081136 crossref_primary_10_1016_j_jsps_2022_10_004 crossref_primary_10_1039_D2TC03058F crossref_primary_10_3233_ADR_200214 crossref_primary_10_1186_s13195_022_01051_2 crossref_primary_10_3389_fnagi_2022_896852 crossref_primary_10_3390_oxygen1020010 crossref_primary_10_1186_s13195_022_00961_5 crossref_primary_10_3171_2021_1_JNS202482 crossref_primary_10_3389_fmed_2023_1335512 crossref_primary_10_1016_j_taap_2023_116512 crossref_primary_10_3390_molecules26061544 crossref_primary_10_1016_j_cbpa_2023_102370 crossref_primary_10_1016_j_neulet_2022_136771 crossref_primary_10_3233_JAD_240002 crossref_primary_10_4018_IJOCI_312223 crossref_primary_10_1556_2060_2022_00020 crossref_primary_10_25279_sak_991294 crossref_primary_10_3389_fneur_2020_538301 crossref_primary_10_1016_j_drudis_2022_07_007 crossref_primary_10_2174_1871527319666200708130745 crossref_primary_10_2174_1381612827666210226123240 crossref_primary_10_1038_s42003_025_07599_7 crossref_primary_10_1016_j_bbrep_2021_101020 crossref_primary_10_1016_j_bmcl_2020_127370 crossref_primary_10_3390_scipharm92020018 crossref_primary_10_1016_j_jconrel_2025_01_019 crossref_primary_10_3389_fnbeh_2021_778456 crossref_primary_10_2174_0118715249278489231128042135 crossref_primary_10_1016_j_fct_2022_112847 crossref_primary_10_2174_0113816128247471231018053737 crossref_primary_10_2478_jtim_2021_0048 crossref_primary_10_3390_cells14050347 crossref_primary_10_1016_j_clinbiochem_2021_12_005 crossref_primary_10_3389_fcell_2023_1146564 crossref_primary_10_3390_ijms21155485 crossref_primary_10_3390_biomedicines10050985 crossref_primary_10_1177_0271678X221082016 crossref_primary_10_3390_ijms22031186 crossref_primary_10_1038_s41598_023_34183_y crossref_primary_10_1016_j_nicl_2022_103274 crossref_primary_10_3390_biomedicines10010169 crossref_primary_10_1007_s41403_025_00522_w crossref_primary_10_3389_fnins_2020_614828 crossref_primary_10_3390_biom11030350 crossref_primary_10_1016_j_gene_2024_148368 crossref_primary_10_1016_j_phrs_2022_106404 crossref_primary_10_3389_fpsyt_2022_967683 crossref_primary_10_1055_a_1696_6741 crossref_primary_10_3389_fnagi_2021_720167 crossref_primary_10_1038_s41581_020_0266_9 crossref_primary_10_1016_j_ahr_2025_100223 crossref_primary_10_3390_molecules27092626 crossref_primary_10_2174_0113894501255093240117092328 crossref_primary_10_2174_1570180819666220210100813 crossref_primary_10_1016_j_neuropharm_2020_108118 crossref_primary_10_1186_s13024_023_00614_7 crossref_primary_10_3389_fneur_2021_640525 crossref_primary_10_3390_nu12051366 crossref_primary_10_1002_alz_12192 crossref_primary_10_3390_ijms26062433 crossref_primary_10_2174_1570159X18666200729093724 crossref_primary_10_1021_acschemneuro_2c00097 crossref_primary_10_1248_cpb_c24_00069 crossref_primary_10_1002_wnan_1898 crossref_primary_10_3390_cells10123533 crossref_primary_10_1021_acsomega_2c07934 crossref_primary_10_3390_jcm10091809 crossref_primary_10_1021_acs_jpcb_4c01578 crossref_primary_10_3233_JAD_215145 crossref_primary_10_1007_s00213_023_06459_8 crossref_primary_10_24304_kjcp_2023_33_4_290 crossref_primary_10_12701_jyms_2021_01683 crossref_primary_10_1038_s41538_023_00246_7 crossref_primary_10_1007_s11357_023_00841_2 crossref_primary_10_3390_biomedicines9101308 crossref_primary_10_1016_j_tet_2025_134468 crossref_primary_10_3389_fnins_2023_1188839 crossref_primary_10_1007_s00706_020_02651_0 crossref_primary_10_1021_acsabm_2c00272 crossref_primary_10_1016_j_ejmech_2022_114248 crossref_primary_10_3390_ijms22147629 crossref_primary_10_1186_s43042_020_00127_8 crossref_primary_10_1016_j_bpj_2020_07_035 crossref_primary_10_1002_wsbm_1591 crossref_primary_10_3233_JAD_230603 crossref_primary_10_1007_s12035_022_03164_z crossref_primary_10_3390_ijms24065991 crossref_primary_10_1002_btm2_10231 crossref_primary_10_14218_JERP_2021_00030 crossref_primary_10_1016_j_phymed_2022_154441 crossref_primary_10_1038_s41598_022_18805_5 crossref_primary_10_3390_biom13101474 crossref_primary_10_7759_cureus_70710 crossref_primary_10_1016_j_neurobiolaging_2024_03_007 crossref_primary_10_1038_s41380_020_0721_9 crossref_primary_10_1039_D3NR05776C crossref_primary_10_1002_trc2_12202 crossref_primary_10_1007_s00421_023_05154_y crossref_primary_10_1038_s41598_022_05862_z crossref_primary_10_1080_01616412_2024_2302271 crossref_primary_10_3389_fphar_2022_943163 crossref_primary_10_52547_phypha_26_3_4 crossref_primary_10_3390_ijms22168570 crossref_primary_10_1159_000525219 crossref_primary_10_1109_ACCESS_2024_3381862 crossref_primary_10_1016_j_arr_2022_101791 crossref_primary_10_3390_microorganisms11010144 crossref_primary_10_1016_j_knosys_2023_111187 crossref_primary_10_1007_s42250_023_00783_4 crossref_primary_10_3390_pharmaceutics12060529 crossref_primary_10_1002_dad2_12251 crossref_primary_10_1039_D1SC00004G crossref_primary_10_1080_01616412_2022_2112368 crossref_primary_10_3233_JAD_215350 crossref_primary_10_1097_JCMA_0000000000000504 crossref_primary_10_1007_s11357_023_00773_x crossref_primary_10_3233_JAD_215239 crossref_primary_10_3390_ijms232314788 crossref_primary_10_1098_rsos_231536 crossref_primary_10_7759_cureus_27194 crossref_primary_10_1038_s41598_023_30303_w crossref_primary_10_1007_s12640_023_00647_2 crossref_primary_10_1002_slct_202300461 crossref_primary_10_1212_NXG_0000000000000610 crossref_primary_10_1002_psp4_12876 crossref_primary_10_3390_biomedicines9081066 crossref_primary_10_1002_gps_5535 crossref_primary_10_1186_s13024_023_00620_9 crossref_primary_10_3390_biomedicines9050581 crossref_primary_10_3390_ijms24043506 crossref_primary_10_3390_ph14090937 crossref_primary_10_1016_j_arr_2022_101654 crossref_primary_10_3390_ijms21155295 crossref_primary_10_1007_s11064_021_03415_w crossref_primary_10_1124_pharmrev_121_000418 crossref_primary_10_1134_S1068162024050212 crossref_primary_10_1038_s41380_022_01476_z crossref_primary_10_3389_fnagi_2021_781468 crossref_primary_10_3390_ijms22158208 crossref_primary_10_14336_AD_2021_1015 crossref_primary_10_3390_vaccines10091527 crossref_primary_10_1016_j_ijbiomac_2022_01_189 crossref_primary_10_3389_fgene_2023_1124431 crossref_primary_10_3389_fnagi_2022_977411 crossref_primary_10_3389_fnut_2023_1185047 crossref_primary_10_3390_bioengineering8120211 crossref_primary_10_1016_j_ejmech_2022_114695 crossref_primary_10_3390_cells10030702 crossref_primary_10_1016_j_jep_2020_113640 crossref_primary_10_1038_s41380_022_01792_4 crossref_primary_10_1016_j_arr_2021_101496 crossref_primary_10_1093_jnen_nlaa093 crossref_primary_10_1177_09514848221138406 crossref_primary_10_1016_j_drudis_2022_01_016 crossref_primary_10_1039_D1MD00036E crossref_primary_10_1007_s11033_021_06520_9 crossref_primary_10_3233_JAD_201021 crossref_primary_10_3390_biomedicines9060594 crossref_primary_10_3390_cells9051215 crossref_primary_10_7717_peerj_12381 crossref_primary_10_3389_fnagi_2023_1149036 crossref_primary_10_1038_s42003_023_04717_1 crossref_primary_10_1073_pnas_2210745120 crossref_primary_10_1002_dad2_12056 crossref_primary_10_3389_fnagi_2021_679837 crossref_primary_10_1016_j_prmcm_2021_100030 crossref_primary_10_1002_adhm_202101854 crossref_primary_10_1016_j_phymed_2024_155822 crossref_primary_10_1080_17460441_2023_2264766 crossref_primary_10_1038_s41598_021_82901_1 crossref_primary_10_2174_0113816128298289240723103828 crossref_primary_10_1186_s13195_024_01423_w crossref_primary_10_1007_s11596_020_2281_2 crossref_primary_10_1080_20415990_2024_2365620 crossref_primary_10_1002_ddr_22113 crossref_primary_10_1016_j_arr_2023_101994 crossref_primary_10_1080_14789450_2021_1918550 crossref_primary_10_1016_j_ajp_2021_102914 crossref_primary_10_59277_RJB_2023_2_01 |
| Cites_doi | 10.1186/1742-2094-11-120 10.1517/14656566.2013.764989 10.1111/j.1750-3639.1991.tb00667.x 10.1186/alzrt272 10.1073/pnas.82.12.4245 10.1136/jnnp-2015-312383 10.3390/antiox7050063 10.1093/hmg/ddt237 10.1016/j.drudis.2018.11.007 10.1016/j.mam.2015.05.005 10.1016/0896-6273(91)90052-2 10.1002/ana.25117 10.3389/fnins.2018.00798 10.1016/j.jalz.2017.06.112 10.1002/ana.410100203 10.1073/pnas.89.13.6075 10.1007/s12017-009-8104-z 10.1073/pnas.1721694115 10.1111/j.1750-3639.1991.tb00671.x 10.1038/325733a0 10.1523/JNEUROSCI.0293-11.2011 10.1002/ana.410410106 10.2353/ajpath.2008.070620 10.1016/0024-3205(78)90011-5 10.15252/emmm.201606210 10.1523/JNEUROSCI.3647-11.2011 10.1016/j.neuron.2014.10.038 10.2165/00002512-200421100-00001 10.7326/0003-4819-148-5-200803040-00009 10.3233/JAD-2011-110977 10.1111/jsr.12782 10.1074/jbc.M202899200 10.18632/oncotarget.22777 10.1056/NEJMoa1705971 10.1038/nature19323 10.1016/j.jalz.2018.02.018 10.1016/S0304-3940(03)00493-2 10.1146/annurev-pharmtox-010716-104837 10.1093/brain/awn320 10.1016/S1474-4422(13)70194-7 10.1016/S0197-4580(96)00213-8 10.1126/science.2933807 10.1080/13543784.2018.1483334 10.1212/01.WNL.0000159740.16984.3C 10.1016/0165-6147(91)90609-V 10.1056/NEJMoa1312889 10.1007/s10571-017-0574-1 10.1016/j.trci.2019.05.008 10.1186/s13195-015-0126-1 10.1093/brain/awx148 10.2174/1570159X11311030005 10.1016/j.apsb.2017.09.001 10.1358/dot.2018.54.12.2899443 10.1016/S0006-291X(84)80190-4 10.3390/ijms19103082 10.1212/WNL.42.3.631 10.1016/S1074-7427(03)00086-8 10.1093/brain/aww017 10.1001/archneur.1995.00540250089017 10.1016/S0140-6736(08)61075-2 10.1016/S1474-4422(09)70299-6 10.1038/nrneurol.2017.162 10.1007/s40266-019-00668-7 10.1074/jbc.273.17.10485 10.1038/nrneurol.2017.38 10.1016/j.neuroscience.2015.08.039 10.3390/molecules24112125 10.1007/s40265-015-0529-0 10.1080/13543784.2017.1265504 10.2119/molmed.2010.00180 10.1016/j.jep.2016.12.005 10.3233/JAD-160763 10.1056/NEJMoa1210951 10.1056/NEJMoa1304839 10.1371/journal.pmed.1002660 10.1038/s41422-019-0216-x 10.1038/s41582-018-0013-z |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2020 BioMed Central Ltd. 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s). 2020 |
| Copyright_xml | – notice: COPYRIGHT 2020 BioMed Central Ltd. – notice: 2020. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s). 2020 |
| DBID | AAYXX CITATION NPM 3V. 7QL 7QO 7QP 7T5 7TK 7TM 7U7 7U9 7X7 7XB 88E 8FD 8FE 8FG 8FH 8FI 8FJ 8FK 8G5 ABJCF ABUWG AEUYN AFKRA AZQEC BBNVY BENPR BGLVJ BHPHI C1K CCPQU DWQXO FR3 FYUFA GHDGH GNUQQ GUQSH H94 HCIFZ K9. L6V LK8 M0S M1P M2O M7N M7P M7S MBDVC P64 PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQGLB PQQKQ PQUKI PTHSS Q9U RC3 7X8 5PM DOA |
| DOI | 10.1186/s12929-019-0609-7 |
| DatabaseName | CrossRef PubMed ProQuest Central (Corporate) Bacteriology Abstracts (Microbiology B) Biotechnology Research Abstracts Calcium & Calcified Tissue Abstracts Immunology Abstracts Neurosciences Abstracts Nucleic Acids Abstracts Toxicology Abstracts Virology and AIDS Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Technology Research Database ProQuest SciTech Collection ProQuest Technology Collection ProQuest Natural Science Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) Research Library (Alumni Edition) Materials Science & Engineering Collection ProQuest Central (Alumni Edition) ProQuest One Sustainability ProQuest Central UK/Ireland ProQuest Central Essentials Biological Science Collection ProQuest Central Technology Collection Natural Science Collection Environmental Sciences and Pollution Management ProQuest One Community College ProQuest Central Korea Engineering Research Database Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student Research Library Prep AIDS and Cancer Research Abstracts SciTech Premium Collection ProQuest Health & Medical Complete (Alumni) ProQuest Engineering Collection ProQuest Biological Science Collection Health & Medical Collection (Alumni Edition) Medical Database Research Library Algology Mycology and Protozoology Abstracts (Microbiology C) Biological Science Database Engineering Database Research Library (Corporate) Biotechnology and BioEngineering Abstracts ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Applied & Life Sciences ProQuest One Academic ProQuest One Academic UKI Edition Engineering Collection ProQuest Central Basic Genetics Abstracts MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef PubMed Publicly Available Content Database Research Library Prep ProQuest Central Student ProQuest Central Essentials Nucleic Acids Abstracts SciTech Premium Collection Environmental Sciences and Pollution Management ProQuest One Applied & Life Sciences ProQuest One Sustainability Health Research Premium Collection Natural Science Collection Health & Medical Research Collection Biological Science Collection ProQuest Central (New) ProQuest Medical Library (Alumni) Engineering Collection Engineering Database Virology and AIDS Abstracts ProQuest Biological Science Collection ProQuest One Academic Eastern Edition ProQuest Hospital Collection ProQuest Technology Collection Health Research Premium Collection (Alumni) Biological Science Database Neurosciences Abstracts ProQuest Hospital Collection (Alumni) Biotechnology and BioEngineering Abstracts ProQuest Health & Medical Complete ProQuest One Academic UKI Edition Engineering Research Database ProQuest One Academic Calcium & Calcified Tissue Abstracts ProQuest One Academic (New) Technology Collection Technology Research Database ProQuest One Academic Middle East (New) ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Natural Science Collection ProQuest Central ProQuest Health & Medical Research Collection Genetics Abstracts ProQuest Engineering Collection Biotechnology Research Abstracts Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts ProQuest Research Library ProQuest Central Basic Toxicology Abstracts ProQuest SciTech Collection ProQuest Medical Library Materials Science & Engineering Collection Immunology Abstracts ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic Publicly Available Content Database CrossRef PubMed |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: 8FG name: ProQuest Technology Collection url: https://search.proquest.com/technologycollection1 sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1423-0127 |
| EndPage | 13 |
| ExternalDocumentID | oai_doaj_org_article_640b65ba43814b239181d28f9bd14a03 PMC6943903 A618772192 31906949 10_1186_s12929_019_0609_7 |
| Genre | Journal Article Review |
| GeographicLocations | United States--US |
| GeographicLocations_xml | – name: United States--US |
| GroupedDBID | --- .86 0R~ 29J 29K 2NJ 2WC 36B 4.4 5GY 5VS 7X7 88E 8FE 8FG 8FH 8FI 8FJ 8G5 AAFWJ AAYXX ABDBF ABJCF ABJNI ABOCM ABUWG ACGFO ACGFS ACIHN ACIWK ACPRK ACUHS ADBBV ADIMF ADRAZ ADUKV AEAQA AEGNC AENEX AEUYN AFKRA AFPKN AFRAH AHBYD AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS AZQEC B0M BAPOH BAWUL BBNVY BCNDV BENPR BFQNJ BGLVJ BGNMA BHPHI BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 CYUIP D-I DIK DU5 DWQXO E3Z EAD EAP EBC EBD EBLON EBS EMB EMK EMOBN EPL ESX F5P FYUFA GNUQQ GROUPED_DOAJ GUQSH GX1 HCIFZ HMCUK HYE IAO IEA IHE IHR INH INR ITC IZQ KDC KQ8 L6V LAK LK8 M1P M2O M48 M4Y M7P M7S ML~ NU0 O5R O5S OK1 P19 P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PTHSS RBZ RHV RNS ROL RPM RPX RRX RSV S27 SBL SDH SOJ SV3 T13 TR2 TUS UKHRP VC2 WJK WK8 ~8M ~KM -A0 3V. ACRMQ ADINQ C24 M~E NPM PMFND 7QL 7QO 7QP 7T5 7TK 7TM 7U7 7U9 7XB 8FD 8FK C1K FR3 H94 K9. M7N MBDVC P64 PJZUB PKEHL PPXIY PQEST PQGLB PQUKI Q9U RC3 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c626t-52073e1e71dbb6c49f570fb1ca845b6c763e24fa70bf79ce1a5e4b4fba18294d3 |
| IEDL.DBID | M48 |
| ISSN | 1423-0127 1021-7770 |
| IngestDate | Wed Aug 27 01:27:41 EDT 2025 Thu Aug 21 14:35:10 EDT 2025 Thu Jul 10 17:49:11 EDT 2025 Fri Jul 25 18:59:42 EDT 2025 Tue Jun 17 21:02:17 EDT 2025 Tue Jun 10 20:46:28 EDT 2025 Wed Feb 19 02:32:13 EST 2025 Thu Apr 24 23:02:16 EDT 2025 Tue Jul 01 00:21:23 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Neuroprotection Anti-tau Alzheimer disease Anti-amyloid Neuroinflammation Cognitive enhancement Clinical trials of drugs |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c626t-52073e1e71dbb6c49f570fb1ca845b6c763e24fa70bf79ce1a5e4b4fba18294d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://doaj.org/article/640b65ba43814b239181d28f9bd14a03 |
| PMID | 31906949 |
| PQID | 2340692389 |
| PQPubID | 54111 |
| PageCount | 13 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_640b65ba43814b239181d28f9bd14a03 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6943903 proquest_miscellaneous_2334239426 proquest_journals_2340692389 gale_infotracmisc_A618772192 gale_infotracacademiconefile_A618772192 pubmed_primary_31906949 crossref_citationtrail_10_1186_s12929_019_0609_7 crossref_primary_10_1186_s12929_019_0609_7 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2020-01-06 |
| PublicationDateYYYYMMDD | 2020-01-06 |
| PublicationDate_xml | – month: 01 year: 2020 text: 2020-01-06 day: 06 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Basel – name: London |
| PublicationTitle | Journal of biomedical science |
| PublicationTitleAlternate | J Biomed Sci |
| PublicationYear | 2020 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | MJ De Leon (609_CR11) 1997; 18 609_CR50 K Murakami (609_CR51) 2019; 24 R Sperling (609_CR18) 2014; 84 609_CR53 609_CR52 B Lawlor (609_CR55) 2018; 15 J Kang (609_CR15) 1987; 325 D Paris (609_CR54) 2011; 17 R Wang (609_CR80) 2017; 57 S Salloway (609_CR41) 2014; 370 MJ Prince (609_CR1) 2015 S Gilman (609_CR39) 2005; 64 J Hardy (609_CR13) 1991; 12 SJ Vos (609_CR49) 2013; 12 A Pinto (609_CR73) 2018; 7 PV Arriagada (609_CR22) 1992; 42 Hao Chi (609_CR29) 2018; 19 CR Jack Jr (609_CR20) 2010; 9 J Sevigny (609_CR43) 2016; 537 T Ikezu (609_CR31) 1998; 273 PB Rosenberg (609_CR2) 2015; 43–44 B Bohrmann (609_CR47) 2012; 28 DJ Selkoe (609_CR62) 2016; 8 B Kumar (609_CR81) 2018; 54 CR Jack Jr (609_CR25) 2018; 14 J Tian (609_CR75) 2017; 15 PJ Coleman (609_CR84) 2017; 57 SS El-Amouri (609_CR35) 2008; 172 RS Doody (609_CR45) 2014; 370 Q Yuan (609_CR74) 2017; 195 T Yang (609_CR77) 2017; 7 GG Glenner (609_CR8) 1984; 120 FP Chong (609_CR69) 2018; 38 JC Polanco (609_CR63) 2018; 14 SY Park (609_CR83) 2017; 8 LM Bierer (609_CR23) 1995; 52 PP De Deyn (609_CR82) 2013; 14 J Cummings (609_CR37) 2019; 5 C Holmes (609_CR61) 2008; 372 R Khoury (609_CR76) 2018; 27 EC Mormino (609_CR19) 2009; 132 D Galimberti (609_CR65) 2017; 26 609_CR67 A Burstein (609_CR64) 2018; 5 MH Mohajeri (609_CR36) 2002; 277 RS Doody (609_CR33) 2013; 369 D Abi-Saab (609_CR48) 2017; 13 I Posadas (609_CR78) 2013; 11 WJ Herring (609_CR85) 2019; 28 609_CR71 EE Congdon (609_CR70) 2018; 14 MM Boccia (609_CR6) 2003; 345 PC May (609_CR34) 2011; 31 GM Bishop (609_CR56) 2004; 21 A Bansal (609_CR72) 1704; 2019 VW Chow (609_CR32) 2010; 12 M Goedert (609_CR10) 1991; 1 D Puzzo (609_CR57) 2015; 307 N Sitaram (609_CR4) 1978; 22 L Hamelin (609_CR26) 2016; 139 G Kolata (609_CR17) 1985; 230 609_CR79 BP Lucey (609_CR60) 2018; 83 P Raina (609_CR7) 2008; 148 DJ Selkoe (609_CR14) 1991; 6 PJ Whitehouse (609_CR3) 1981; 10 LS Honig (609_CR46) 2018; 378 L Bakota (609_CR66) 2016; 76 609_CR44 SS Sisodia (609_CR30) 1992; 89 E Shokri-Kojori (609_CR58) 2018; 115 YS Ju (609_CR59) 2017; 140 AE Power (609_CR5) 2003; 80 K Beyreuther (609_CR12) 1991; 1 ER Zimmer (609_CR28) 2014; 11 WF Goure (609_CR42) 2014; 6 CL Masters (609_CR9) 1985; 82 Jinping Wang (609_CR38) 2016; 87 C Wiessner (609_CR40) 2011; 31 M Novak (609_CR68) 2018; 12 S Gunawardena (609_CR16) 2013; 22 T Gomez-Isla (609_CR21) 1997; 41 D Gomez-Nicola (609_CR27) 2015; 7 N Okamura (609_CR24) 2017; 13 |
| References_xml | – volume: 11 start-page: 120 issue: 1 year: 2014 ident: 609_CR28 publication-title: J Neuroinflammation doi: 10.1186/1742-2094-11-120 – volume: 15 start-page: 532 issue: 15 year: 2017 ident: 609_CR75 publication-title: Curr Vasc Pharmacol – volume: 14 start-page: 459 issue: 4 year: 2013 ident: 609_CR82 publication-title: Expert Opin Pharmacother doi: 10.1517/14656566.2013.764989 – volume: 1 start-page: 241 issue: 4 year: 1991 ident: 609_CR12 publication-title: Brain Pathol (Zurich, Switzerland) doi: 10.1111/j.1750-3639.1991.tb00667.x – volume: 6 start-page: 42 issue: 4 year: 2014 ident: 609_CR42 publication-title: Alzheimers Res Ther doi: 10.1186/alzrt272 – ident: 609_CR53 – volume: 82 start-page: 4245 issue: 12 year: 1985 ident: 609_CR9 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.82.12.4245 – volume: 87 start-page: 993 issue: 9 year: 2016 ident: 609_CR38 publication-title: Journal of Neurology, Neurosurgery & Psychiatry doi: 10.1136/jnnp-2015-312383 – volume: 7 start-page: 63 issue: 5 year: 2018 ident: 609_CR73 publication-title: Antioxidants. doi: 10.3390/antiox7050063 – volume: 22 start-page: 3828 issue: 19 year: 2013 ident: 609_CR16 publication-title: Hum Mol Genet doi: 10.1093/hmg/ddt237 – ident: 609_CR71 doi: 10.1016/j.drudis.2018.11.007 – volume: 5 start-page: 149 issue: 2 year: 2018 ident: 609_CR64 publication-title: J Prev Alzheimer's Dis – volume: 43–44 start-page: 25 year: 2015 ident: 609_CR2 publication-title: Mol Asp Med doi: 10.1016/j.mam.2015.05.005 – volume: 6 start-page: 487 issue: 4 year: 1991 ident: 609_CR14 publication-title: Neuron. doi: 10.1016/0896-6273(91)90052-2 – volume: 83 start-page: 197 issue: 1 year: 2018 ident: 609_CR60 publication-title: Ann Neurol doi: 10.1002/ana.25117 – volume: 12 start-page: 798 year: 2018 ident: 609_CR68 publication-title: Front Neurosci doi: 10.3389/fnins.2018.00798 – volume: 13 start-page: P252 issue: 7 year: 2017 ident: 609_CR48 publication-title: Alzheimer's Dementia: J Alzheimer's Assoc doi: 10.1016/j.jalz.2017.06.112 – volume: 10 start-page: 122 issue: 2 year: 1981 ident: 609_CR3 publication-title: Ann Neurol doi: 10.1002/ana.410100203 – ident: 609_CR44 – volume: 89 start-page: 6075 issue: 13 year: 1992 ident: 609_CR30 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.89.13.6075 – volume: 12 start-page: 1 issue: 1 year: 2010 ident: 609_CR32 publication-title: NeuroMolecular Med doi: 10.1007/s12017-009-8104-z – volume: 115 start-page: 4483 issue: 17 year: 2018 ident: 609_CR58 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1721694115 – volume: 1 start-page: 279 issue: 4 year: 1991 ident: 609_CR10 publication-title: Brain Pathol (Zurich, Switzerland) doi: 10.1111/j.1750-3639.1991.tb00671.x – volume: 325 start-page: 733 issue: 6106 year: 1987 ident: 609_CR15 publication-title: Nature doi: 10.1038/325733a0 – volume: 31 start-page: 9323 issue: 25 year: 2011 ident: 609_CR40 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.0293-11.2011 – volume: 41 start-page: 17 issue: 1 year: 1997 ident: 609_CR21 publication-title: Ann Neurol doi: 10.1002/ana.410410106 – volume: 172 start-page: 1342 issue: 5 year: 2008 ident: 609_CR35 publication-title: Am J Pathol doi: 10.2353/ajpath.2008.070620 – volume: 22 start-page: 1555 issue: 17 year: 1978 ident: 609_CR4 publication-title: Life Sci doi: 10.1016/0024-3205(78)90011-5 – volume: 8 start-page: 595 issue: 6 year: 2016 ident: 609_CR62 publication-title: EMBO Mol Med doi: 10.15252/emmm.201606210 – volume: 31 start-page: 16507 issue: 46 year: 2011 ident: 609_CR34 publication-title: J Neurosci doi: 10.1523/JNEUROSCI.3647-11.2011 – volume: 84 start-page: 608 issue: 3 year: 2014 ident: 609_CR18 publication-title: Neuron. doi: 10.1016/j.neuron.2014.10.038 – volume: 21 start-page: 621 issue: 10 year: 2004 ident: 609_CR56 publication-title: Drugs Aging doi: 10.2165/00002512-200421100-00001 – volume: 148 start-page: 379 issue: 5 year: 2008 ident: 609_CR7 publication-title: Ann Intern Med doi: 10.7326/0003-4819-148-5-200803040-00009 – volume: 28 start-page: 49 issue: 1 year: 2012 ident: 609_CR47 publication-title: J Alzheimers Dis doi: 10.3233/JAD-2011-110977 – volume: 28 start-page: e12782 issue: 2 year: 2019 ident: 609_CR85 publication-title: J Sleep Res doi: 10.1111/jsr.12782 – volume: 277 start-page: 35460 issue: 38 year: 2002 ident: 609_CR36 publication-title: J Biol Chem doi: 10.1074/jbc.M202899200 – volume: 8 start-page: 110380 issue: 66 year: 2017 ident: 609_CR83 publication-title: Oncotarget. doi: 10.18632/oncotarget.22777 – volume: 378 start-page: 321 issue: 4 year: 2018 ident: 609_CR46 publication-title: N Engl J Med doi: 10.1056/NEJMoa1705971 – volume: 537 start-page: 50 issue: 7618 year: 2016 ident: 609_CR43 publication-title: Nature doi: 10.1038/nature19323 – volume: 14 start-page: 535 issue: 4 year: 2018 ident: 609_CR25 publication-title: Alzheimer's Dementia : J Alzheimer's Assoc doi: 10.1016/j.jalz.2018.02.018 – volume: 345 start-page: 97 issue: 2 year: 2003 ident: 609_CR6 publication-title: Neurosci Lett doi: 10.1016/S0304-3940(03)00493-2 – volume: 57 start-page: 509 year: 2017 ident: 609_CR84 publication-title: Annu Rev Pharmacol Toxicol doi: 10.1146/annurev-pharmtox-010716-104837 – volume: 132 start-page: 1310 issue: Pt 5 year: 2009 ident: 609_CR19 publication-title: Brain J Neurol doi: 10.1093/brain/awn320 – volume: 12 start-page: 957 issue: 10 year: 2013 ident: 609_CR49 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(13)70194-7 – volume: 18 start-page: 1 issue: 1 year: 1997 ident: 609_CR11 publication-title: Neurobiol Aging doi: 10.1016/S0197-4580(96)00213-8 – volume: 230 start-page: 1152 issue: 4730 year: 1985 ident: 609_CR17 publication-title: Science (New York, NY) doi: 10.1126/science.2933807 – volume: 27 start-page: 523 issue: 6 year: 2018 ident: 609_CR76 publication-title: Expert Opin Investig Drugs doi: 10.1080/13543784.2018.1483334 – volume: 64 start-page: 1553 issue: 9 year: 2005 ident: 609_CR39 publication-title: Neurology. doi: 10.1212/01.WNL.0000159740.16984.3C – volume: 2019 start-page: 78 year: 1704 ident: 609_CR72 publication-title: Brain Res – volume: 12 start-page: 383 issue: 10 year: 1991 ident: 609_CR13 publication-title: Trends Pharmacol Sci doi: 10.1016/0165-6147(91)90609-V – volume: 370 start-page: 311 issue: 4 year: 2014 ident: 609_CR45 publication-title: N Engl J Med doi: 10.1056/NEJMoa1312889 – volume: 38 start-page: 965 issue: 5 year: 2018 ident: 609_CR69 publication-title: Cell Mol Neurobiol doi: 10.1007/s10571-017-0574-1 – volume: 5 start-page: 272 year: 2019 ident: 609_CR37 publication-title: Alzheimer's Dementia: Transl Res Clin Interv doi: 10.1016/j.trci.2019.05.008 – volume: 7 start-page: 42 issue: 1 year: 2015 ident: 609_CR27 publication-title: Alzheimers Res Ther doi: 10.1186/s13195-015-0126-1 – volume-title: World Alzheimer report 2015: the global impact of dementia: an analysis of prevalence, incidence, cost and trends year: 2015 ident: 609_CR1 – volume: 140 start-page: 2104 issue: 8 year: 2017 ident: 609_CR59 publication-title: Brain J Neurol doi: 10.1093/brain/awx148 – volume: 11 start-page: 298 issue: 3 year: 2013 ident: 609_CR78 publication-title: Curr Neuropharmacol doi: 10.2174/1570159X11311030005 – volume: 7 start-page: 611 issue: 6 year: 2017 ident: 609_CR77 publication-title: Acta Pharm Sin B doi: 10.1016/j.apsb.2017.09.001 – volume: 54 start-page: 713 issue: 12 year: 2018 ident: 609_CR81 publication-title: Drugs Today (Barcelona, Spain: 1998) doi: 10.1358/dot.2018.54.12.2899443 – volume: 120 start-page: 885 issue: 3 year: 1984 ident: 609_CR8 publication-title: Biochem Biophys Res Commun doi: 10.1016/S0006-291X(84)80190-4 – volume: 19 start-page: 3082 issue: 10 year: 2018 ident: 609_CR29 publication-title: International Journal of Molecular Sciences doi: 10.3390/ijms19103082 – volume: 42 start-page: 631 issue: 3 Pt 1 year: 1992 ident: 609_CR22 publication-title: Neurology. doi: 10.1212/WNL.42.3.631 – volume: 80 start-page: 178 issue: 3 year: 2003 ident: 609_CR5 publication-title: Neurobiol Learn Mem doi: 10.1016/S1074-7427(03)00086-8 – volume: 139 start-page: 1252 issue: Pt 4 year: 2016 ident: 609_CR26 publication-title: Brain J Neurol doi: 10.1093/brain/aww017 – ident: 609_CR67 – volume: 52 start-page: 81 issue: 1 year: 1995 ident: 609_CR23 publication-title: Arch Neurol doi: 10.1001/archneur.1995.00540250089017 – volume: 372 start-page: 216 issue: 9634 year: 2008 ident: 609_CR61 publication-title: Lancet (London, England) doi: 10.1016/S0140-6736(08)61075-2 – volume: 9 start-page: 119 issue: 1 year: 2010 ident: 609_CR20 publication-title: Lancet Neurol doi: 10.1016/S1474-4422(09)70299-6 – ident: 609_CR50 – volume: 14 start-page: 22 issue: 1 year: 2018 ident: 609_CR63 publication-title: Nat Rev Neurol doi: 10.1038/nrneurol.2017.162 – ident: 609_CR79 doi: 10.1007/s40266-019-00668-7 – volume: 273 start-page: 10485 issue: 17 year: 1998 ident: 609_CR31 publication-title: J Biol Chem doi: 10.1074/jbc.273.17.10485 – volume: 13 start-page: 197 year: 2017 ident: 609_CR24 publication-title: Nat Rev Neurol doi: 10.1038/nrneurol.2017.38 – volume: 307 start-page: 26 year: 2015 ident: 609_CR57 publication-title: Neuroscience. doi: 10.1016/j.neuroscience.2015.08.039 – volume: 24 start-page: 2125 issue: 11 year: 2019 ident: 609_CR51 publication-title: Molecules. doi: 10.3390/molecules24112125 – volume: 76 start-page: 301 issue: 3 year: 2016 ident: 609_CR66 publication-title: Drugs. doi: 10.1007/s40265-015-0529-0 – volume: 26 start-page: 97 issue: 1 year: 2017 ident: 609_CR65 publication-title: Expert Opin Investig Drugs doi: 10.1080/13543784.2017.1265504 – volume: 17 start-page: 149 issue: 3–4 year: 2011 ident: 609_CR54 publication-title: Mol Med (Cambridge, Mass) doi: 10.2119/molmed.2010.00180 – volume: 195 start-page: 1 year: 2017 ident: 609_CR74 publication-title: J Ethnopharmacol doi: 10.1016/j.jep.2016.12.005 – volume: 57 start-page: 1041 issue: 4 year: 2017 ident: 609_CR80 publication-title: J Alzheimers Dis doi: 10.3233/JAD-160763 – volume: 369 start-page: 341 issue: 4 year: 2013 ident: 609_CR33 publication-title: N Engl J Med doi: 10.1056/NEJMoa1210951 – volume: 370 start-page: 322 issue: 4 year: 2014 ident: 609_CR41 publication-title: N Engl J Med doi: 10.1056/NEJMoa1304839 – volume: 15 start-page: e1002660 issue: 9 year: 2018 ident: 609_CR55 publication-title: PLoS Med doi: 10.1371/journal.pmed.1002660 – ident: 609_CR52 doi: 10.1038/s41422-019-0216-x – volume: 14 start-page: 399 issue: 7 year: 2018 ident: 609_CR70 publication-title: Nat Rev Neurol doi: 10.1038/s41582-018-0013-z |
| SSID | ssj0015987 |
| Score | 2.6676176 |
| SecondaryResourceType | review_article |
| Snippet | Alzheimer disease (AD) accounts for 60–70% of dementia cases. Given the seriousness of the disease and continual increase in patient numbers, developing... Alzheimer disease (AD) accounts for 60-70% of dementia cases. Given the seriousness of the disease and continual increase in patient numbers, developing... Abstract Alzheimer disease (AD) accounts for 60–70% of dementia cases. Given the seriousness of the disease and continual increase in patient numbers,... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 18 |
| SubjectTerms | Advertising executives Alzheimer disease Alzheimer's disease Amyloidosis Anti-Alzheimer's disease agents Anti-amyloid Anti-tau Aspartate Atrophy Biomarkers Brain Cholinesterase Cholinesterase inhibitors Clinical trials Clinical trials of drugs Cognitive ability Dementia Dementia disorders Disease control Diseases Drug therapy Drugs Glutamate receptors Hypotheses Immunotherapy Inflammation Magnetic resonance imaging Medical research Memory Metabolism N-methyl-D-aspartate N-Methyl-D-aspartic acid receptors Neurodegeneration Neurodegenerative diseases Neuroinflammation Neuroprotection Neurotransmitters Pathogenesis Peptides Pharmaceutical industry Product development Psychological symptoms Reason Review Signs and symptoms Tau protein Time Trends |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlkNJLSdOX07SoUCgUTGRZD-u4KQ2hkJ4ayE3o2QS23rKPQ_PrM2NrlzWF9tKrJYH1eUYznyV9Q8gH0WjHVFK1YjECQckoeWtM7ZzvYmYh8IBE8eqburwWX2_kzV6pLzwTNsoDj8CdKcG8kt6hFJXwvDUQkiLvsvGxEW7U-YSYtyVTZf9AApUue5hNp85WENU4ngvCG_fM1HoShQax_j-X5L2YND0vuReALo7I05I50tn4xs_Io9Qfk8OxluTvY_L4quySPye8iH3O6VCTY0UXmUL2TONy82NFIUuls_n9bbr7mZa0bNC8INcXX75_vqxLbYQ6AAVZA38E30xN0k30XgVhstQs-ya4Tkh4AMtG4iI7zXzWJqTGySS8yN4BoTAiti_JQb_o02tClWylyYFlnRuI19FIBzlDFwCyzJMRFWFbrGwowuFYv2JuBwLRKTvCawFei_BaXZFPuyG_RtWMv3U-xw-w64iC18MDMANbzMD-ywwq8hE_n0W3hJcLrtwugCmiwJWdqaYDIgH5bEVOJz3BncK0eWsAtrjzyvIWLwgDKKYi73fNOBKPqPVpscE-g5giIFiRV6O97KYE6xxeMIbRemJJkzlPW_q720HsG4a1hrUn_wOkN-QJx98F-AdJnZKD9XKT3kJOtfbvBvd5AN14GUg priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3di9QwEB_0RPFF9PyqnlJBEIRyaZsmzZOs4nEI55MH-xbyeXewbs_t7oP-9c602XpFuNd8QDLJfGUmvwF4z0tpmAiiEMx7dFAiQd4qVRhjWx-Zc5UjR_Hsuzg959-WzTI9uPUprXIvEwdB7TtHb-THVU1_NFHBqE_XvwqqGkXR1VRC4y7cI-gySumSy8nhQk09FMij6tVoRcp9VLNsxXGPeq6iTCH6g89UIWd6aYDv_19I39BS8wzKGyrp5DE8SrZkvhgP_wncCetDuD9Wl_x9CA_OUtz8KVQJ_nOVD1U6-ryLOdrTud_sLvoc7dZ8sfpzGa5-hk2eQjbP4Pzk648vp0WqllA4dEq26FEit4YyyNJbKxxXsZEs2tKZljfYgIIkVDwayWyUyoXSNIFbHq1BF0NxXz-Hg3W3Di8hF03dqOhYlLFEDe5VY9CKaB2SLFZB8QzYnlbaJShxqmix0oNL0Qo9klcjeTWRV8sMPk5TrkccjdsGf6YDmAYSBPbQ0G0udOIoLTizorGGMMq4rWqFtoqv2qisL7lhdQYf6Pg0MSouzpn03wC3SJBXeiHKFl0LtHAzOJqNRAZz8-79BdCJwXv97zpm8G7qppmUtLYO3Y7GDPCKSMEMXoz3ZdoSSj76coyz5ewmzfY871lfXQ7w3zitVqx-dfuyXsPDip4G6LVIHMHBdrMLb9B-2tq3A5P8Be01E8w priority: 102 providerName: ProQuest |
| Title | Clinical trials of new drugs for Alzheimer disease |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/31906949 https://www.proquest.com/docview/2340692389 https://www.proquest.com/docview/2334239426 https://pubmed.ncbi.nlm.nih.gov/PMC6943903 https://doaj.org/article/640b65ba43814b239181d28f9bd14a03 |
| Volume | 27 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3fi9QwEB7uB4ovoqee1XOpIAhCNW3TpHkQ2ZPbO4Q9RFzYt5Ckyd3B2tXuLnj-9c50u-sVD8GXPjTJsvk6k5nJJN8AvOKpNEx4kQhWVRigBKK8VSoxxpZVYM5ljgLF8bk4m_BP02K6A5vyVh2Ai1tDO6onNWlmb3_-uP6ACv--VfhSvFugzcro1A_dp2cqkbuwj4ZJkp6O-Z-kQqHaenkpehAJZVy7JOetP9EzUy2b_99r9g2j1T9QecNCjR7A_c61jIdrWXgIO74-gDvrYpPXB3B33KXRH0HWsYHO4rZoxyKehxjd67hqVheLGN3YeDj7demvvvkm7jI4j2EyOvn68SzpiickDmOUJQaYqLw-9TKtrBWOq1BIFmzqTMkLfIHris94MJLZIJXzqSk8tzxYgxGH4lX-BPbqee2fQiyKvFDBsSADYicqVRh0KkqHkIXMKx4B22ClXccsTgUuZrqNMEqh1_BqhFcTvFpG8GY75PuaVuNfnY_pA2w7EiN2-2LeXOhOwbTgzIrCGqIs4zbLFbouVVYGZauUG5ZH8Jo-nyZJwj_nTHf9AKdIDFh6KNISIw10eCM46vVEfXP95o0A6I246iynG8QIiorg5baZRtIZttrPV9SnZVtEBCM4XMvLdkq4ENINZBwte5LUm3O_pb66bNnAcViuWP7sfxB9Dvcy2jegrSRxBHvLZuVfoHO1tAPYlVOJz3J0OoD945Pzz18G7UYFPk-n6aBVqd8Feh-w |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Zb9QwEB6VIo4XBOUKFAgSCAkpquM4TvyA0HJUW9rtUyvtm7Edu6207JY9hMqP4jcyk2NphNS3vvqI4vEc39ieGYA3Ii0Mk14mklUVOiiBUt4qlRhjyyow57gjR3F0KIfH4ts4H2_Any4Whp5VdjqxVtTVzNEZ-Q7PKEYTDYz6eP4zoapRdLvaldBo2GLfX_xCl23xYe8L7u9bzne_Hn0eJm1VgcQheF-i54Vc7VNfpJW10gkV8oIFmzpTihwbUOA8F8EUzIZCOZ-a3AsrgjUIxZWoMvzuDbiJhpeRRBXjtYOHyKAuyEfVshG1Ft0talrKnQXaVU4vkyjmn6mk6NnBulzA_0bhklXsv9i8ZAJ378O9FrvGg4bZHsCGn27Braaa5cUW3B619_QPgbfpRidxXRVkEc9CjPg9ruark0WMODkeTH6f-rMffh63V0SP4Pha6PgYNqezqX8KscyzXAXHQhFSRAyVyg2iltIhyQL3SkTAOlpp16YupwoaE127MKXUDXk1klcTeXURwfv1lPMmb8dVgz_RBqwHUsrtumE2P9GtBGspmJW5NZQTTVieKcRGFS-DslUqDMsieEfbp0kx4M8508Y34BIpxZYeyLREVwYRdQTbvZEo0K7f3TGAbhXKQv9j_wher7tpJj2Sm_rZisbU6RyRghE8afhlvSTUtBTijLOLHif11tzvmZ6d1unGcVqmWPbs6t96BXeGR6MDfbB3uP8c7nI6lqCTKrkNm8v5yr9A7La0L2uBieH7dUvoX62dUYc |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+trials+of+new+drugs+for+Alzheimer+disease&rft.jtitle=Journal+of+biomedical+science&rft.au=Huang%2C+Li-Kai&rft.au=Chao%2C+Shu-Ping&rft.au=Hu%2C+Chaur-Jong&rft.date=2020-01-06&rft.issn=1423-0127&rft.eissn=1423-0127&rft.volume=27&rft.issue=1&rft_id=info:doi/10.1186%2Fs12929-019-0609-7&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12929_019_0609_7 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1423-0127&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1423-0127&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1423-0127&client=summon |